Cell Biosciences Launches Two New Platforms

SANTA CLARA, California, April 15, 2010 - Cell Biosciences, Inc., a provider of innovative protein analysis tools
to life science researchers, today announced the launch of two new platforms
for ultrasensitive protein characterization. Both platforms will be unveiled
at the American Association for Cancer Research (AACR) 101st Annual Meeting,
April 17-21, 2010 in Washington, DC (booth 719).

The new NanoPro(TM) 100 system builds upon the success of the NanoPro
CB1000 platform, which was introduced in 2009. The NanoPro CB1000 has been
adopted by many of the world's foremost drug development and translational
medicine researchers, with nearly 30 systems placed in the past nine months.
The NanoPro 100 offers the same analytical power as the high-throughput
NanoPro CB1000 system, but in a compact, benchtop system designed for
lower-throughput laboratories and individual investigators. The NanoPro 100
is the first system that gives researchers access to revolutionary NanoPro
technology for under US$100,000.

NanoPro assay technology enables detailed characterization of proteins in
extremely small and precious samples, such as tumor micro-biopsies and
isolated stem cell populations. NanoPro assays are used to uncover
fundamental mechanisms controlling cell proliferation and cell death, to
accelerate the development of new therapeutics, and to help identify new
prognostic and diagnostic disease biomarkers. Current NanoPro customers
include leading institutions and companies in the fields of cancer research,
stem cell biology, diabetes, and drug development.

Also being launched at AACR 2010 is the FluorChem(R) E Digital Darkroom,
which sets a new standard for high-performance chemiluminescent Western blot
and gel imaging. The FluorChem E system features unparalleled sensitivity and
resolution for Western blot analysis, and represents the first member of Cell
Biosciences' next-generation imaging product line. The system's innovative
design incorporates state-of-the-art CCD technology and intuitive touch
screen control for effortless analysis of chemiluminescent, colorimetric, and
UV-fluorescent samples. FluorChem E's novel imaging software enables
convenient file access from any internet-enabled device, such as Apple's
iPhone(R) or iPad(TM).

"Cell Biosciences is committed to expanding its product leadership
position in protein analysis," commented Walter Ausserer, Ph.D., Vice
President of Marketing at Cell Biosciences. "We believe that customers will
be delighted by the innovative features and exceptional performance of the
NanoPro 100 and FluorChem E systems, and that these new platforms will be key
drivers for our continued growth."

ABOUT CELL BIOSCIENCES

Cell Biosciences is a private life sciences company focused on defining
the future of protein analysis. The Company develops instrumentation systems,
sample preparation systems, software and assay products that drive
discoveries in fields ranging from fundamental protein research to biomarker
discovery and personalized medicine. With an installed base of over 10,000
systems, its customers include leading research institutions, pharmaceutical
and biotechnology companies worldwide. Cell Biosciences is headquartered in
Santa Clara, California. For more information, visit
www.cellbiosciences.com.

Walter Ausserer, Ph.D., Vice President of Marketing, Cell Biosciences, Inc., +1-408-510-5503, wausserer at cellbiosciences.com